DOCSLIB.ORG

Supplementary Data

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Supplementary Data SUPPLEMENTARY DATA Supplementary Table 1. GTDF does not bind to ionotropic glutamate receptors. Wistar rat cerebral cortex (for AMPA receptor, and NMDA receptor agonist, glycine, phencyclidine and polyamine sites), Wistar rat whole brain (minus cerebellum, for Kainate receptor) or whole Wistar rat brain (for non- selective glutamate binding) were incubated with indicated radioligands in absence or presence of indicated doses of GTDF. % inhibition of radioligand binding was calculated using standard formula. Threshold inhibition was set at 50% for consideration of inhibition. GTDF Receptor, % Radi Specific Kd of Nonspec Incubat Incubati Concentra assay inhibition oliga binding radiolig ific ion on time, tion (µM) of specific nd activity and competit buffer temperat radioligand of or ure binding radiolig and AMPA 1.0 mM 50 mM L- Tris- 5.0 Glutami HCl, nM 90% KD1= c acid pH 7.4, 10 3 [3H] 200 AMP 0.018 mM A µM KSCN 1 15 KD2 = 0.1 -7 0.99 90min, µM 4°C Kainate 5.0 1.0 mM 50 mM 60 nM 80% KD = L- Tris- minutes, 10 7 [3H] Glutami HCl, 4°C AMP 0.012 c acid pH 7.4 A µM 1 2 0.1 -1 NMDA, 2.0 1.0 mM 50 mM 20 Agonism nM L- Tris- minutes, [3H] 70% KD = Glutami HCl, 4°C 10 -3 CGP c acid pH 7.4 - 3965 0.019 3 µM 1 7 0.1 6 NMDA, 0.33 50 mM 30 Glycine nM HEPES minutes, [3H] 85% KD = 10.0 µM , pH 4°C 10 7 7.7 MDL 105,5 0.006 MDL 19 µM 105,519 1 3 ©2014 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1619/-/DC1 SUPPLEMENTARY DATA 0.1 3 NMDA, 1.0 µM 45 Phencycli Dizocilp minutes, dine 4.0 ine (+)- 25°C nM MK- [3H] 94% KD = 801) 10 2 0.0084 TCP µM 10 mM Tris- 1 -5 HCl, 0.1 -2 pH 7.4 NMDA, 2.0 50 mM 2 hours, Polyamin nM Tris- 4°C e [3H] 80% KD = HCl, 10 4 pH 7.4 Ifenp 0.026 rodil µM 10.0 µM 1 -8 Ifenprod 0.1 -3 il Glutamate 50 mM 30 , Non- 3.75 Tris- minutes, selective nM HCl, 37°C [3H] 90% KD = pH 7.4, 10 17 L- 2.5 mM Gluta CaCl2 mic 0.29 acid µM 50.0 µM L- 1 13 Glutami 0.1 14 c acid ©2014 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1619/-/DC1 SUPPLEMENTARY DATA Supplementary Table 2. GTDF does not activate or repress metabotropic glutamate receptors at its active dose but quercetin activates mGlu2, and suppresses mGlu4, -6 and -8 activity. Modulation of metabotropic glutamate receptor activities by GTDF or quercetin at their pharmacologically active concentrations was assessed. mGlu1, -3, -5 activities were assessed by an aequorin assay, mGlu2 and -7 activities were assessed by cAMP assay, mGlu4, -6 and -8 were assessed by GTPγS binding. PAM; positive allosteric modulator. Threshold activation or repression was set at 50%. % activation or repression beyond the threshold is in red. Assay mode Conc Co- Compound (µM) Agonist Antagonist PAM Addition % % % % activation inhibition activation activation Receptor: mGlu1 GTDF 1 0.15 -8.98 0.951 2.09 0.1 0.35 1.6 0.791 0.87 Quercetin 1000 -0.049 16.41 2.02 -3.38 100 -0.37 -8.911 6.97 23.58 Receptor: mGlu2 GTDF 1 -10.64 19.62 -17.95 0.1 -7.76 9.56 8.59 Quercetin 1000 -2.17 18.32 12.65 100 117.85* -7.6 284.27* Receptor: mGlu3 GTDF 1 2.38 5.06 -3.55 6.39 0.1 0.78 -12.26 -3.52 3.94 Quercetin 1000 0.36 -6.58 -18.96 -0.061 100 4.75 -11.32 -5.068 24.67 Receptor: mGlu4 GTDF 1 5.04 -4.44 4.14 0.1 1.63 -6.16 5.87 Quercetin 1000 -23.15 86.97 -33.79 100 -7.75 31.65 -14.11 Receptor: mGlu5 GTDF 1 0.4 -1.15 -3.35 2.61 0.1 0.04 3.35 -5.14 3.69 Quercetin 1000 0.11 14.66 -0.74 0.64 100 -0.07 -30.92 8.72 3.55 Receptor: ©2014 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1619/-/DC1 SUPPLEMENTARY DATA mGlu6 GTDF 1 -2.24 -0.04 -15.39 0.1 -6.65 -4.91 -4.82 Quercetin 1000 -136.684 201.61 -141.74 100 -20.7469 58.63 -39.7 Receptor: mGlu7 GTDF 1 16.46 11.21 8.68 0.1 19.05 0.22 0.836 Quercetin 1000 18.96 13.68 10.19 100 23.22 -4.71 8.94 Receptor: mGlu8 GTDF 1 1.15 15.33 10.26 0.1 -4.24 -1.28 4.6 Quercetin 1000 -72.89 159.53 -64.26 100 -14.3 58.17 -10.91 ©2014 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1619/-/DC1 SUPPLEMENTARY DATA Supplementary Table 3. GTDF is not a GPCR agonist. GTDF at its pharmacologically active dose (0.1µM) or high dose (10µM) was assessed for its ability to modulate GPCR signalling using pathhunter β-arrestin assay for the indicated GPCRs. Threshold for consideration as an activator was set at 50%. GTDF GTDF Assay % % GPCR ID Conc Conc Mode Activity Activity (µM) (µM) ADCYAP1R1 Agonist 0.1 -2% 10 -2% ADORA3 Agonist 0.1 -7% 10 -9% ADRA1B Agonist 0.1 -1% 10 -2% ADRA2A Agonist 0.1 -3% 10 -1% ADRA2B Agonist 0.1 -5% 10 -3% ADRA2C Agonist 0.1 -2% 10 -1% ADRB1 Agonist 0.1 -1% 10 -1% ADRB2 Agonist 0.1 0% 10 -1% AGTR1 Agonist 0.1 -3% 10 -2% AGTRL1 Agonist 0.1 -1% 10 -2% AVPR1A Agonist 0.1 -5% 10 -4% AVPR1B Agonist 0.1 -2% 10 -1% AVPR2 Agonist 0.1 -2% 10 -4% BDKRB1 Agonist 0.1 -5% 10 0% BDKRB2 Agonist 0.1 -3% 10 -3% BRS3 Agonist 0.1 -6% 10 -2% C5AR1 Agonist 0.1 -2% 10 -2% C5LR2 Agonist 0.1 -1% 10 -14% CALCR Agonist 0.1 -1% 10 -11% CALCR + RAMP2 Agonist 0.1 -7% 10 -4% CALCR + RAMP3 Agonist 0.1 -6% 10 -25% CALCRL + RAMP1 Agonist 0.1 -4% 10 -1% CALCRL + RAMP2 Agonist 0.1 -4% 10 -1% CALCRL + RAMP3 Agonist 0.1 -3% 10 -1% CCKAR Agonist 0.1 -2% 10 -1% CCKBR Agonist 0.1 -5% 10 -4% CCR10 Agonist 0.1 -3% 10 -3% CCR2 Agonist 0.1 -2% 10 -2% CCR3 Agonist 0.1 -5% 10 -4% CCR4 Agonist 0.1 -5% 10 -1% CCR5 Agonist 0.1 -4% 10 -1% CCR6 Agonist 0.1 -2% 10 -3% ©2014 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1619/-/DC1 SUPPLEMENTARY DATA CCR7 Agonist 0.1 8% 10 -5% CCR8 Agonist 0.1 0% 10 -3% CCR9 Agonist 0.1 -5% 10 -5% CHRM1 Agonist 0.1 -4% 10 -5% CHRM2 Agonist 0.1 -3% 10 -1% CHRM3 Agonist 0.1 -5% 10 -2% CHRM4 Agonist 0.1 6% 10 -4% CHRM5 Agonist 0.1 -7% 10 -29% CMKLR1 Agonist 0.1 -2% 10 -4% CMKOR1 Agonist 0.1 -8% 10 -2% CNR1 Agonist 0.1 0% 10 -2% CNR2 Agonist 0.1 0% 10 -4% CRHR1 Agonist 0.1 -2% 10 -1% CRHR2 Agonist 0.1 -3% 10 -1% CRTH2 Agonist 0.1 -3% 10 -5% CX3CR1 Agonist 0.1 -2% 10 0% CXCR1 Agonist 0.1 -10% 10 -1% CXCR2 Agonist 0.1 -2% 10 -2% CXCR3 Agonist 0.1 -3% 10 -3% CXCR4 Agonist 0.1 7% 10 9% CXCR5 Agonist 0.1 -8% 10 -6% CXCR6 Agonist 0.1 -2% 10 -3% DRD1 Agonist 0.1 -6% 10 -3% DRD2L Agonist 0.1 -4% 10 2% DRD2S Agonist 0.1 -5% 10 -3% DRD3 Agonist 0.1 7% 10 -14% DRD4 Agonist 0.1 -2% 10 -2% DRD5 Agonist 0.1 -4% 10 -2% EDG1 Agonist 0.1 -3% 10 -5% EDG2 Agonist 0.1 -1% 10 -2% EDG3 Agonist 0.1 -4% 10 -5% EDG4 Agonist 0.1 2% 10 1% EDG5 Agonist 0.1 -2% 10 7% EDG6 Agonist 0.1 2% 10 -12% EDG7 Agonist 0.1 -4% 10 -2% EDG8 Agonist 0.1 0% 10 1% EDNRA Agonist 0.1 -7% 10 -3% EDNRB Agonist 0.1 -3% 10 -3% F2R Agonist 0.1 9% 10 -2% F2RL1 Agonist 0.1 -1% 10 -1% F2RL3 Agonist 0.1 -3% 10 -1% ©2014 American Diabetes Association. Published online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db13-1619/-/DC1 SUPPLEMENTARY DATA FPR1 Agonist 0.1 -10% 10 -4% FPRL1 Agonist 0.1 -2% 10 -1% FSHR Agonist 0.1 6% 10 -11% GALR1 Agonist 0.1 -4% 10 -1% GALR2 Agonist 0.1 -5% 10 -6% GCGR Agonist 0.1 -3% 10 -1% GHSR1A Agonist 0.1 0% 10 -2% GIPR Agonist 0.1 -3% 10 -13% GLP1R Agonist 0.1 -1% 10 -1% GLP2R Agonist 0.1 -1% 10 -2% GPR1 Agonist 0.1 -4% 10 -3% GPR109A Agonist 0.1 -11% 10 -4% GPR119 Agonist 0.1 -4% 10 -4% GPR120 Agonist 0.1 -1% 10 -7% GPR35 Agonist 0.1 -4% 10 -3% GPR92 Agonist 0.1 -7% 10 -6% GRPR Agonist 0.1 -1% 10 -2% HCRTR1 Agonist 0.1 -3% 10 -1% HCRTR2 Agonist 0.1 -3% 10 -1% HRH1 Agonist 0.1 0% 10 -1% HRH2 Agonist 0.1 -2% 10 -1% HRH3 Agonist 0.1 -14% 10 -6% HTR1A Agonist 0.1 -2% 10 -2% HTR1B Agonist 0.1 -4% 10 -4% HTR1E Agonist 0.1 -7% 10 -1% HTR1F Agonist 0.1 -3% 10 -2% HTR2A Agonist 0.1 3% 10 -11% HTR2C Agonist 0.1 -3% 10 -1% HTR5A Agonist 0.1 -1% 10 -13% KISS1R Agonist 0.1 -3% 10 -4% LHCGR Agonist 0.1 1% 10 -8% LTB4R Agonist 0.1 -3% 10 -3% MC1R Agonist 0.1 -1% 10 -1% MC3R Agonist 0.1 7% 10 -10% MC4R Agonist 0.1 -4% 10 -12% MC5R Agonist 0.1 -8% 10 -5% MCHR1 Agonist 0.1 -1% 10 -5% MCHR2 Agonist 0.1 -3% 10 -2% MLNR Agonist 0.1 -3% 10 -4% MRGPRX2 Agonist 0.1 -6% 10 -2% MTNR1A Agonist 0.1 0% 10 -4% ©2014 American Diabetes Association.
Load more

Recommended publications
  • Chimeric Gpcrs Mimic Distinct Signaling Pathways and Modulate Microglia Responses
    bioRxiv preprint doi: https://doi.org/10.1101/2021.06.21.449162; this version posted June 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. Chimeric GPCRs mimic distinct signaling pathways and modulate microglia responses Rouven Schulz, Medina Korkut-Demirbaş, Gloria Colombo, Sandra Siegert† Author affiliation: Institute of Science and Technology (IST) Austria, Am Campus 1, 3400 Klosterneuburg, Austria † Corresponding author: [email protected] Keywords: G protein coupled receptor (GPCR), DREADD, β2-adrenergic receptor (β2AR/ADRB2), microglia, inflammation, GPR65, GPR109A/HCAR2 Abstract G protein-coupled receptors (GPCRs) regulate multiple processes ranging from cell growth and immune responses to neuronal signal transmission. However, ligands for many GPCRs remain unknown, suffer from off-target effects or have poor bioavailability. Additional challenges exist to dissect cell type-specific responses when the same GPCR is expressed on different cells within the body. Here, we overcome these limitations by engineering DREADD-based GPCR chimeras that selectively bind their agonist clozapine-N-oxide (CNO) and mimic a GPCR-of-interest. We show that the chimeric DREADD-β2-adrenergic receptor (β2AR/ADRB2) triggers comparable responses to levalbuterol on second messenger and kinase activity, post-translational modifications, and protein-protein interactions. Moreover, we successfully recapitulate β2AR-mediated filopodia formation in microglia, a β2AR-expressing immune cell that can drive inflammation in the nervous system. To further dissect microglial inflammation, we compared DREADD-β2AR with two additionally designed DREADD-based chimeras mimicking GPR65 and GPR109A/HCAR2, both enriched in microglia.
    [Show full text]
  • G Protein-Coupled Receptors As New Therapeutic Targets for Type 2 Diabetes
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Diabetologia (2016) 59:229–233 DOI 10.1007/s00125-015-3825-z MINI-REVIEW G protein-coupled receptors as new therapeutic targets for type 2 diabetes Frank Reimann1 & Fiona M. Gribble 1 Received: 31 October 2015 /Accepted: 9 November 2015 /Published online: 12 December 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract G protein-coupled receptors (GPCRs) in the gut– GLP1R Glucagon-like peptide 1 receptor brain–pancreatic axis are key players in the postprandial con- GPBAR1 G protein-coupled bile acid receptor trol of metabolism and food intake. A number of intestinally GPCR G protein-coupled receptor located receptors have been implicated in the chemo-detection of ingested nutrients, and in the pancreatic islets and nervous system GPCRs play essential roles in the detection of many Therapeutics that promote insulin secretion have been a main- hormones and neurotransmitters. Because of the diversity, stay of type 2 diabetes treatment for many years. However, cell-specific expression and ‘druggability’ of the GPCR su- with the rising impact of obesity on the incidence of type 2 perfamily, these receptors are popular targets for therapeutic diabetes comes an increasing need to target body weight as development. This review will outline current and potential well as blood glucose control. Recent years have witnessed an future approaches to develop GPCR agonists for the treatment increasing interest in the gut endocrine system as a source of of type 2 diabetes.
    [Show full text]
  • The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands
    The Activation of the Glucagon-Like Peptide-1 (GLP-1) Receptor by Peptide and Non-Peptide Ligands Clare Louise Wishart Submitted in accordance with the requirements for the degree of Doctor of Philosophy of Science University of Leeds School of Biomedical Sciences Faculty of Biological Sciences September 2013 I Intellectual Property and Publication Statements The candidate confirms that the work submitted is her own and that appropriate credit has been given where reference has been made to the work of others. This copy has been supplied on the understanding that it is copyright material and that no quotation from the thesis may be published without proper acknowledgement. The right of Clare Louise Wishart to be identified as Author of this work has been asserted by her in accordance with the Copyright, Designs and Patents Act 1988. © 2013 The University of Leeds and Clare Louise Wishart. II Acknowledgments Firstly I would like to offer my sincerest thanks and gratitude to my supervisor, Dr. Dan Donnelly, who has been nothing but encouraging and engaging from day one. I have thoroughly enjoyed every moment of working alongside him and learning from his guidance and wisdom. My thanks go to my academic assessor Professor Paul Milner whom I have known for several years, and during my time at the University of Leeds he has offered me invaluable advice and inspiration. Additionally I would like to thank my academic project advisor Dr. Michael Harrison for his friendship, help and advice. I would like to thank Dr. Rosalind Mann and Dr. Elsayed Nasr for welcoming me into the lab as a new PhD student and sharing their experimental techniques with me, these techniques have helped me no end in my time as a research student.
    [Show full text]
  • A Guide to Glutamate Receptors
    A guide to glutamate receptors 1 Contents Glutamate receptors . 4 Ionotropic glutamate receptors . 4 - Structure ........................................................................................................... 4 - Function ............................................................................................................ 5 - AMPA receptors ................................................................................................. 6 - NMDA receptors ................................................................................................. 6 - Kainate receptors ............................................................................................... 6 Metabotropic glutamate receptors . 8 - Structure ........................................................................................................... 8 - Function ............................................................................................................ 9 - Group I: mGlu1 and mGlu5. .9 - Group II: mGlu2 and mGlu3 ................................................................................. 10 - Group III: mGlu4, mGlu6, mGlu7 and mGlu8 ............................................................ 10 Protocols and webinars . 11 - Protocols ......................................................................................................... 11 - Webinars ......................................................................................................... 12 References and further reading . 13 Excitatory synapse pathway
    [Show full text]
  • Trace Amine-Associated Receptor 1 Activation Regulates Glucose-Dependent
    Trace amine-associated receptor 1 activation regulates glucose-dependent insulin secretion in pancreatic beta cells in vitro by ©Arun Kumar A thesis submitted to the School of Graduate Studies in partial fulfillment of the requirements for the degree of Master of Science Department of Biochemistry, Faculty of Science Memorial University of Newfoundland FEBRUARY 2021 St. John’s, Newfoundland and Labrador i Abstract Trace amines are a group of endogenous monoamines which exert their action through a family of G protein-coupled receptors known as trace amine-associated receptors (TAARs). TAAR1 has been reported to regulate insulin secretion from pancreatic beta cells in vitro and in vivo. This study investigates the mechanism(s) by which TAAR1 regulates insulin secretion. The insulin secreting rat INS-1E -cell line was used for the study. Cells were pre-starved (30 minutes) and then incubated with varying concentrations of glucose (2.5 – 20 mM) or KCl (3.6 – 60 mM) for 2 hours in the absence or presence of various concentrations of the selective TAAR1 agonist RO5256390. Secreted insulin per well was quantified using ELISA and normalized to the total protein content of individual cultures. RO5256390 significantly (P < 0.0001) increased glucose- stimulated insulin secretion in a dose-dependent manner, with no effect on KCl-stimulated insulin secretion. Affymetrix-microarray data analysis identified genes (Gnas, Gng7, Gngt1, Gria2, Cacna1e, Kcnj8, and Kcnj11) whose expression was associated with changes in TAAR1 in response to changes in insulin secretion in pancreatic beta cell function. The identified potential links to TAAR1 supports the regulation of glucose-stimulated insulin secretion through KATP ion channels.
    [Show full text]
  • Receptor Internalization Assays
    REF: P30214 RECEPTOR INTERNALIZATION ASSAYS - PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE TYPE I RECEPTOR - Product name: ADCYAP1R1-tGFP (PAC1-tGFP) / U2OS cell line -7 Ec50 PACAP-38: 1.06 x 10 M Z´: 0.73+/- 0.02 INNOVATIVE TECHNOLOGIES IN BIOLOGICAL SYSTEMS, S.L. Parque Tecnológico Bizkaia, Edifício 502, 1ª Planta | 48160 | Derio | Bizkaia Tel.: +34 944005355 | Fax: +34 946579925 VAT No. [email protected] | www.innoprot.com ESB95481909 Product Name: ADCYAP1R1-tGFP_U2OS Reference: P30214 Rep. Official Full Name: Pituitary adenylate cyclase- activating polypeptide type I receptor DNA Accession Number: Gene Bank AY366498 Host Cell: U2OS References: P30214: 2 vials of 3 x 106 proliferative cells P30214-DA: 1 vial of 2 x 106 division-arrested cells Storage: Liquid Nitrogen Assay Briefly description About ADCYAP1R1 Each vial of ADCYAP1R1 Internalization Assay Pituitary adenylate cyclase-activating Cell Line contains U2OS cells stably expressing polypeptide type I receptor, also known as human Pituitary adenylate cyclase-activating PAC1 is a protein that in humans is encoded by polypeptide type I receptor tagged in the N- the ADCYAP1R1 gene. ADCYAP1R1 is a terminus with tGFP protein. membrane-associated protein and shares significant homology with members of the Innoprot’s ADCYAP1R1-tGFP Internalization glucagon/secretin receptor family. This receptor Assay Cell Line has been designed to assay binds pituitary adenylate cyclase activating potential agonists/ antagonists against peptide (PACAP) mediating several biological ADCYAP1R1, modulating its activation and the activities and it is positively coupled to following redistribution process inside the cells. adenylate cyclase. This cell line will allow the image analysis of the stimuli induced by the compounds.
    [Show full text]
  • Gastrointestinal Defense Mechanisms
    REVIEW CURRENT OPINION Gastrointestinal defense mechanisms Hyder Said a,b and Jonathan D. Kaunitzb,c Purpose of review To summarize and illuminate the recent findings regarding gastroduodenal mucosal defense mechanisms and the specific biomolecules involved in regulating this process, such as glucagon-like peptides (GLPs). Recent findings There has been a growing interest in luminal nutrient chemosensing and its physiological effects throughout the digestive system. From the ingestion of food in the oral cavity to the processing and absorption of nutrients in the intestines, nutrient chemosensing receptors signal the production and release of numerous bioactive peptides from enteroendocrine cells, such as the proglucagon-derived peptides. There has been a major emphasis on two proglucagon-derived peptides, namely GLP-1 and GLP-2, due to their apparent beneficial effect on gut structure, function, and on metabolic processes. As an incretin, GLP-1 not only enhances the effect and release of insulin on pancreatic bcells but also has been implicated in having trophic effects on the intestinal epithelium. In addition, GLP-2, the other major proglucagon-derived peptide, has potent intestinotrophic effects, such as increasing the rate of mucosal stem cell proliferation, mucosal blood flow, and fluid absorption, as well as augmenting the rate of duodenal bicarbonate secretion to improve gastric mucosal health and longevity. Summary Understanding the mechanisms underlying nutrient chemosensing and how it relates to GLP release can further elucidate how the gut functions in response to cellular changes and disturbances. Furthermore, a more in-depth comprehension of GLP release and its tissue-specific effects will help improve the utility of GLP-1 and GLP-2 receptor agonists in clinical settings.
    [Show full text]
  • Edinburgh Research Explorer
    Edinburgh Research Explorer International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list Citation for published version: Davenport, AP, Alexander, SPH, Sharman, JL, Pawson, AJ, Benson, HE, Monaghan, AE, Liew, WC, Mpamhanga, CP, Bonner, TI, Neubig, RR, Pin, JP, Spedding, M & Harmar, AJ 2013, 'International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands', Pharmacological reviews, vol. 65, no. 3, pp. 967-86. https://doi.org/10.1124/pr.112.007179 Digital Object Identifier (DOI): 10.1124/pr.112.007179 Link: Link to publication record in Edinburgh Research Explorer Document Version: Publisher's PDF, also known as Version of record Published In: Pharmacological reviews Publisher Rights Statement: U.S. Government work not protected by U.S. copyright General rights Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights. Take down policy The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact [email protected] providing details, and we will remove access to the work immediately and investigate your claim. Download date: 02. Oct. 2021 1521-0081/65/3/967–986$25.00 http://dx.doi.org/10.1124/pr.112.007179 PHARMACOLOGICAL REVIEWS Pharmacol Rev 65:967–986, July 2013 U.S.
    [Show full text]
  • Lysophosphatidic Acid Signaling in the Nervous System
    Neuron Review Lysophosphatidic Acid Signaling in the Nervous System Yun C. Yung,1,3 Nicole C. Stoddard,1,2,3 Hope Mirendil,1 and Jerold Chun1,* 1Molecular and Cellular Neuroscience Department, Dorris Neuroscience Center, The Scripps Research Institute, La Jolla, CA 92037, USA 2Biomedical Sciences Graduate Program, University of California, San Diego School of Medicine, La Jolla, CA 92037, USA 3Co-first author *Correspondence: [email protected] http://dx.doi.org/10.1016/j.neuron.2015.01.009 The brain is composed of many lipids with varied forms that serve not only as structural components but also as essential signaling molecules. Lysophosphatidic acid (LPA) is an important bioactive lipid species that is part of the lysophospholipid (LP) family. LPA is primarily derived from membrane phospholipids and signals through six cognate G protein-coupled receptors (GPCRs), LPA1-6. These receptors are expressed on most cell types within central and peripheral nervous tissues and have been functionally linked to many neural pro- cesses and pathways. This Review covers a current understanding of LPA signaling in the nervous system, with particular focus on the relevance of LPA to both physiological and diseased states. Introduction LPA synthesis/degradative enzymes (reviewed in Sigal et al., The human brain is composed of approximately 60%–70% lipids 2005; Brindley and Pilquil, 2009; Perrakis and Moolenaar, by dry weight (Svennerholm et al., 1994). These lipids can be 2014). In view of the broad neurobiological influences of LPA divided into two major pools, structural and signaling, which signaling, its dysregulation may lead to diverse neuropathologies include well-known families such as cholesterol, fatty acids, ei- (Bandoh et al., 2000; Houben and Moolenaar, 2011; Yung et al., cosanoids, endocannabinoids, and prostaglandins (Figure 1).
    [Show full text]
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels
    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
    [Show full text]
  • Metabolite Sensing Gpcrs: Promising Therapeutic Targets for Cancer Treatment?
    cells Review Metabolite Sensing GPCRs: Promising Therapeutic Targets for Cancer Treatment? Jesús Cosín-Roger 1,*, Dolores Ortiz-Masia 2 , Maria Dolores Barrachina 3 and Sara Calatayud 3 1 Hospital Dr. Peset, Fundación para la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, FISABIO, 46017 Valencia, Spain 2 Departament of Medicine, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] 3 Departament of Pharmacology and CIBER, Faculty of Medicine, University of Valencia, 46010 Valencia, Spain; [email protected] (M.D.B.); [email protected] (S.C.) * Correspondence: [email protected]; Tel.: +34-963851234 Received: 30 September 2020; Accepted: 21 October 2020; Published: 23 October 2020 Abstract: G-protein-coupled receptors constitute the most diverse and largest receptor family in the human genome, with approximately 800 different members identified. Given the well-known metabolic alterations in cancer development, we will focus specifically in the 19 G-protein-coupled receptors (GPCRs), which can be selectively activated by metabolites. These metabolite sensing GPCRs control crucial processes, such as cell proliferation, differentiation, migration, and survival after their activation. In the present review, we will describe the main functions of these metabolite sensing GPCRs and shed light on the benefits of their potential use as possible pharmacological targets for cancer treatment. Keywords: G-protein-coupled receptor; metabolite sensing GPCR; cancer 1. Introduction G-protein-coupled receptors (GPCRs) are characterized by a seven-transmembrane configuration, constitute the largest and most ubiquitous family of plasma membrane receptors, and regulate virtually all known physiological processes in humans [1,2]. This family includes almost one thousand genes that were initially classified on the basis of sequence homology into six classes (A–F), where classes D and E were not found in vertebrates [3].
    [Show full text]
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
    [Show full text]